8 ud af 8 tidsskrifter valgt, søgeord (covid-19) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
109 emner vises.
51
Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024
Morbidity and Mortality Weekly Report (MMWR), 2.02.2024
Tilføjet 2.02.2024
This report describes vaccine effectiveness for the updated COVID-19 vaccine in preventing symptomatic SARS-CoV-2 infection.
Læs mere
52
Respiratory Virus Surge: Diagnosing COVID-19 vs RSV, Flu
Medscape Infectious Diseases, 1.02.2024
Tilføjet 1.02.2024
Amid the current winter wave surge of respiratory virus cases, how challenging is it for physician\'s to distinguish between, diagnose, and treat COVID-19 vs RSV and influenza? Medscape Medical News
Læs mere
53
Vaccination coverage in the EU/EEA during Autumn 2023 campaigns
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
Nearly 20 million people aged 60 years and above received COVID-19 vaccines during the autumn / winter campaign in the EU/EEA
Læs mere
54
Interim COVID-19 vaccination coverage in the EU/EEA during the 2023–24 season campaigns
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
This report presents an interim description of COVID-19 vaccine coverage in the European Union/European Economic Area (EU/EEA) between 1 September 2023 and January 2024.
Læs mere
55
Age-dependent influenza infection patterns and subtype circulation in Denmark, in seasons 2015/16 to 2021/22
Hanne-Dorthe Emborg, Amanda Bolt Botnen, Jens Nielsen, Lasse S. Vestergaard, Frederikke Kristensen Lomholt, Charlotte Munkstrup, Karina Lauenborg Møller, Charlotte Kjelsø, Steen Hulthin Rasmussen and Ramona Trebbien
Eurosurveillance latest updates, 26.01.2024
Tilføjet 26.01.2024
BackgroundInfluenza was almost absent for 2 years following the implementation of strict public health measures to prevent the spread of SARS-CoV-2. The consequence of this on infections in different age groups is not yet known. AimTo describe the age groups infected with the influenza virus in 2021/22, the first post-pandemic influenza season in Denmark, compared with the previous six seasons, and subtypes circulating therein. MethodsInfection and hospitalisation incidences per season and age group were estimated from data in Danish registries. Influenza virus subtypes and lineages were available from samples sent to the National Influenza Centre at Statens Serum Institut. ResultsTest incidence followed a similar pattern in all seasons, being highest in 0–1-year-olds and individuals over 75 years, and lowest in 7–14-year-olds and young people 15 years to late twenties. When the influenza A virus subtypes A(H3N2) and A(H1N1)pdm09 co-circulated in seasons 2015/16 and 2017/18 to 2019/20, the proportion of A(H1N1)pdm09 was higher in 0–1-year-olds and lower in the over 85-year-olds compared with the overall proportion of A(H1N1)pdm09 in these seasons. The proportion of A(H3N2) was higher in the over 85 years age group compared with the overall proportion of A(H3N2). The 2016/17 and 2021/22 seasons were dominated by A(H3N2) but differed in age-specific trends, with the over 85 years age group initiating the 2016/17 season, while the 2021/22 season was initiated by the 15–25-year-olds, followed by 7–14-year-olds. ConclusionThe 2021/22 influenza season had a different age distribution compared with pre-COVID-19 pandemic seasons.
Læs mere
56
Authors’ response: Added value of backward contact tracing for COVID-19
Timo Louis Boelsums, Maaike Buskermolen and on behalf of all co-authors of the original article
Eurosurveillance latest updates, 26.01.2024
Tilføjet 26.01.2024
57
Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 - Veterans Health Administration, March-September 2022
Morbidity and Mortality Weekly Report (MMWR), 26.01.2024
Tilføjet 26.01.2024
This report describes a review of immunosuppressed patients with nonsevere COVID-19 who were not treated with an antiviral drug.
Læs mere
58
Picture of COVID-19 in Europe Is Complex
Medscape Infectious Diseases, 24.01.2024
Tilføjet 24.01.2024
Infection rates are declining overall, but continuing vigilance is crucial, said WHO. Medscape Medical News
Læs mere
59
Forskere har fundet ud af, hvem der især blev ramt af senfølger efter covid-19
Statens Serum Institut, 23.01.2024
Tilføjet 23.01.2024
Personer over 35 år, kvinder, overvægtige og mennesker med lidelser som depression og astma var særligt udsatte for senfølger efter covid-19 infektion tidligt i pandemien, konkluderer ny undersøgelse.
Læs mere
60
Time trends and modifiable factors of COVID-19 contact tracing coverage, Geneva, Switzerland, June 2020 to February 2022
Denis Mongin, Nils Bürgisser, the Covid-SMC Study Group and Delphine Sophie Courvoisier
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
BackgroundContact tracing was one of the central non-pharmaceutical interventions implemented worldwide to control the spread of SARS-CoV-2, but its effectiveness depends on its ability to detect contacts. AimEvaluate the proportion of secondary infections captured by the contact tracing system in Geneva. MethodsWe analysed 166,892 concomitant infections occurring at the same given address from June 2020 until February 2022 using an extensive operational database of SARS-CoV-2 tests in Geneva. We used permutation to compare the total number of secondary infections occurring at the same address with that reported through manual contact tracing. ResultsContact tracing captured on average 41% of secondary infections, varying from 23% during epidemic peaks to 60% during low epidemic activity. People living in wealthy neighbourhoods were less likely to report contacts (odds ratio (OR): 1.6). People living in apartment buildings were also less likely to report contacts than those living in a house (OR: 1.1–3.1) depending on the SARS-CoV-2 variant, the building size and the presence of shops. This under-reporting of contacts in apartment buildings decreased during periods of mandatory wearing of face masks and restrictions on private gatherings. ConclusionContact tracing alone did not detect sufficient secondary infections to reduce the spread of SARS-CoV-2. Campaigns targeting specific populations, such as those in wealthy areas or apartment buildings, could enhance coverage. Additionally, measures like wearing face masks, improving ventilation and implementing restrictions on gatherings should also be considered to reduce infections resulting from interactions that may not be perceived as high risk.
Læs mere
61
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, Verónica Gomez, Maria-Louise Borg, Goranka Petrović, Róisín Duffy, François E Dufrasne, Ralf Dürrwald, Mihaela Lazar, Ligita Jancoriene, Beatrix Oroszi, Petr Husa, Jennifer Howard, Aryse Melo, Francisco Pozo, Gloria Pérez-Gimeno, Jesús Castilla, Ausenda Machado, Aušra Džiugytė, Svjetlana Karabuva, Margaret Fitzgerald, Sébastien Fierens, Kristin Tolksdorf, Silvia-Odette Popovici, Auksė Mickienė, Gergő Túri, Lenka Součková, Nathalie Nicolay, Angela MC Rose and on behalf of the European Hospital Vaccine Effectiveness Group
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
Læs mere
62
Study Estimates Post-COVID Risk for Alopecia Areata
Medscape Infectious Diseases, 15.01.2024
Tilføjet 15.01.2024
The incidence of alopecia areata in patients with COVID-19 was significantly higher than that in the uninfected controls, in a large Korean cohort study. MDedge News
Læs mere
63
RespiCast: the new European Respiratory Diseases Forecasting Hub
ECDC
ECDC COVID-19 updates, 15.01.2024
Tilføjet 15.01.2024
The European Respiratory Diseases Forecasting Hub (RespiCast) is open for weekly submission of several respiratory disease indicators such as influenza-like-illness, acute respiratory infection and COVID-19.
Læs mere
64
Impact of sex and gender on post-COVID-19 syndrome, Switzerland, 2020
Caroline E Gebhard, Claudia Sütsch, Pimrapat Gebert, Bianca Gysi, Susan Bengs, Atanas Todorov, Manja Deforth, Philipp K Buehler, Alexander Meisel, Reto A Schuepbach, Annelies S Zinkernagel, Silvio D Brugger, Claudio Acevedo, Dimitri Patriki, Benedikt Wiggli, Jürg H Beer, Andrée Friedl, Raphael Twerenbold, Gabriela M Kuster, Hans Pargger, Sarah Tschudin-Sutter, Joerg C Schefold, Thibaud Spinetti, Chiara Henze, Mina Pasqualini, Dominik F Sager, Lilian Mayrhofer, Mirjam Grieder, Janna Tontsch, Fabian C Franzeck, Pedro D Wendel Garcia, Daniel A Hofmaenner, Thomas Scheier, Jan Bartussek, Ahmed Haider, Muriel Grämer, Nidaa Mikail, Alexia Rossi, Núria Zellweger, Petra Opić, Angela Portmann, Roland von Känel, Aju P Pazhenkottil, Michael Messerli, Ronny R Buechel, Philipp A Kaufmann, Valerie Treyer, Martin Siegemund, Ulrike Held, Vera Regitz-Zagrosek and Catherine Gebhard
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
BackgroundWomen are overrepresented among individuals with post-acute sequelae of SARS-CoV-2 infection (PASC). Biological (sex) as well as sociocultural (gender) differences between women and men might account for this imbalance, yet their impact on PASC is unknown. AimWe assessed the impact of sex and gender on PASC in a Swiss population. MethodOur multicentre prospective cohort study included 2,856 (46% women, mean age 44.2 ± 16.8 years) outpatients and hospitalised patients with PCR-confirmed SARS-CoV-2 infection. ResultsAmong those who remained outpatients during their first infection, women reported persisting symptoms more often than men (40.5% vs 25.5% of men; p
Læs mere
65
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19-Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease - United States, September 2022-March 2023
Morbidity and Mortality Weekly Report (MMWR), 12.01.2024
Tilføjet 12.01.2024
This report describes how bivalent COVID-19 vaccines were nearly 50% effective in preventing COVID-19-related thromboembolic events among adults aged 65 and older and those on dialysis.
Læs mere
66
Spain Makes Masks Mandatory in Healthcare Centres Amid Flu, COVID Peak
Medscape Infectious Diseases, 12.01.2024
Tilføjet 12.01.2024
Spanish Health Minister Monica Garcia made wearing masks mandatory in healthcare centres around the country from Wednesday as the country faces a peak of flu and COVID-19... Reuters Health Information
Læs mere
67
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023
Mario Fontán-Vela, Esther Kissling, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Hanne-Dorthe Emborg, Massimo Fabiani, Alberto Mateo-Urdiales, Ala'a AlKerwi, Susanne Schmitz, Jesús Castilla, Iván Martínez-Baz, Brechje de Gier, Susan Hahné, Hinta Meijerink, Jostein Starrfelt, Baltazar Nunes, Constantino Caetano, Tarik Derrough, Anthony Nardone, Susana Monge and VEBIS-Lot4 working group
Eurosurveillance latest updates, 5.01.2024
Tilføjet 5.01.2024
To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021–July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65–79-year-olds.
Læs mere
68
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023
C Henri van Werkhoven, Anne-Wil Valk, Bente Smagge, Hester E de Melker, Mirjam J Knol, Susan JM Hahné, Susan van den Hof and Brechje de Gier
Eurosurveillance latest updates, 5.01.2024
Tilføjet 5.01.2024
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6–74.3), VE against ICU admission was 73.3% (95% CI: 42.2–87.6).
Læs mere
69
Covid-19-smittebølge har toppet
Statens Serum Institut, 3.01.2024
Tilføjet 3.01.2024
De seneste ugers udbredte smitte med fem forskellige luftvejssygdomme ser nu ud til at have toppet for flere af sygdommene. Særligt covid-19, der har fyldt mest, ser ud til at være på retur, og hvis udviklingen holder stik, vil det forventeligt kunne mærkes på sygdomsbilledet de kommende uger.
Læs mere
70
Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2023
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes influenza, updated COVID-19, and respiratory syncytial virus vaccination coverage among adults.
Læs mere
71
Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents - National Healthcare Safety Network, United States, December 2023
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes respiratory syncytial virus, influenza, and COVID-19 vaccination coverage among nursing home residents.
Læs mere
72
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes data from two randomized, double-blind clinical trials that investigated COVID-19 rebound following treatment with or without nirmatrelvir/ritonavir.
Læs mere
73
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
CDC reviewed COVID-19 rebound studies among patients who did and did not receive antiviral treatment.
Læs mere
74
Impact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022
Wieke Altorf-van der Kuil, Cornelia CH Wielders, Romy D Zwittink, Sabine C de Greeff, Dave A. Dongelmans, Ed J Kuijper, Daan W Notermans, Annelot F Schoffelen and on behalf of the study collaborators ISIS-AR study group
Eurosurveillance latest updates, 15.12.2023
Tilføjet 15.12.2023
BackgroundThe COVID-19 pandemic resulted in adaptation in infection control measures, increased patient transfer, high occupancy of intensive cares, downscaling of non-urgent medical procedures and decreased travelling. AimTo gain insight in the influence of these changes on antimicrobial resistance (AMR) prevalence in the Netherlands, a country with a low AMR prevalence, we estimated changes in demographics and prevalence of six highly resistant microorganisms (HRMO) in hospitalised patients in the Netherlands during COVID-19 waves (March–June 2020, October 2020–June 2021, October 2021–May 2022 and June–August 2022) and interwaves (July–September 2020 and July–September 2021) compared with pre-COVID-19 (March 2019–February 2020). MethodsWe investigated data on routine bacteriology cultures of hospitalised patients, obtained from 37 clinical microbiological laboratories participating in the national AMR surveillance. Demographic characteristics and HRMO prevalence were calculated as proportions and rates per 10,000 hospital admissions. ResultsAlthough no significant persistent changes in HRMO prevalence were detected, some relevant non-significant patterns were recognised in intensive care units. Compared with pre-COVID-19 we found a tendency towards higher prevalence of meticillin-resistant Staphylococcus aureus during waves and lower prevalence of multidrug-resistant Pseudomonas aeruginosa during interwaves. Additionally, during the first three waves, we observed significantly higher proportions and rates of cultures with Enterococcus faecium (pooled 10% vs 6% and 240 vs 120 per 10,000 admissions) and coagulase-negative Staphylococci (pooled 21% vs 14% and 500 vs 252 per 10,000 admissions) compared with pre-COVID-19. ConclusionWe observed no substantial changes in HRMO prevalence in hospitalised patients during the COVID-19 pandemic.
Læs mere
75
Notes from the Field: COVID-19 Pandemic-Related Changes in Blood Lead Screening - Chicago, Illinois, 2017-2022
Morbidity and Mortality Weekly Report (MMWR), 14.12.2023
Tilføjet 14.12.2023
This report describes decreases in blood lead level testing among young children during the COVID-19 pandemic.
Læs mere
76
Reporting Protocol for integrated respiratory virus surveillance, version 1.4
ECDC
ECDC COVID-19 updates, 13.12.2023
Tilføjet 13.12.2023
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
77
Anxiety, Depression Soared in Young Adults During Pandemic
Medscape Infectious Diseases, 8.12.2023
Tilføjet 8.12.2023
More than a third of young adults living in the US during the COVID-19 pandemic experienced anxiety and/or depression, an outcome that may be related to economic or social uncertainty. Medscape Medical News
Læs mere
78
Factors associated with parental intention to vaccinate their child against influenza, Finland, February to March, 2022: a web-based survey
Idil Hussein, Simopekka Vänskä, Jonas Sivelä, Tuija Leino and Hanna Nohynek
Eurosurveillance latest updates, 8.12.2023
Tilføjet 8.12.2023
BackgroundInfluenza vaccination for children aged 6 months to 6 years is included in the national vaccination programme in Finland. Although all vaccines in the programme are free of charge, national coverage of influenza vaccination among children under 3 years and 3–6 years during 2020/21 was 43% and 35% respectively, with regional differences. AimTo assess factors underlying parental vaccination intention in order to increase influenza vaccine uptake among children. MethodsWe conducted a web-based survey among parents (n = 17,844) of randomly selected eligible children (aged 6 months–6 years) in February–March 2022 in five Finnish municipalities from regions of high and low coverage. Logistic regressions were used to determine associations between vaccination intention and e.g. sociodemographic factors, attitudes and knowledge. Linkage to the national vaccination register was used to confirm realisation of vaccination intention after the study. ResultsParticipation rate was 13% (n = 2,322 parents). Influenza knowledge, trust in official information, responding parent’s education level, adherence to the vaccination programme, number of children and changes in attitudes towards vaccination since COVID-19 were all associated with intention to vaccinate. Vaccination intention for children was 64%, and realised vaccination 51%. ConclusionDespite the low participation rate, both vaccinated and unvaccinated children were represented. Influenza vaccine uptake is not dependent on a single factor. Our results identified the need for open dialogue between parents and healthcare professionals, as the lack of vaccine being offered by healthcare professionals was the most reported reason for not vaccinating.
Læs mere
79
COVID, Flu Rates Rising Nationwide, but RSV May Have Peaked
Medscape Infectious Diseases, 6.12.2023
Tilføjet 6.12.2023
COVID-19 appears to be heading for a holiday season increase across most of the United States. WebMD Health News
Læs mere
80
COVID Vaccines Lower Risk of Serious Illness in Kids
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
Two doses of an mRNA COVID-19 vaccine reduced hospitalizations and emergency department visits by 40%. Medscape Medical News
Læs mere
81
Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
Anastasia Chatzilena, Catherine Hyams, Rob Challen, Robin Marlow, Jade King, David Adegbite, Jane Kinney, Madeleine Clout, Nick Maskell, Jennifer Oliver, Adam Finn, Leon Danon and on behalf of The Avon CAP Research Group
Eurosurveillance latest updates, 1.12.2023
Tilføjet 1.12.2023
BackgroundUnderstanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest. AimWe assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters. MethodsWe performed a prospective single-centre test-negative design case–control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation. ResultsWe included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9–67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0–65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose. ConclusionsBoth fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses.
Læs mere
82
SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023
Morbidity and Mortality Weekly Report (MMWR), 1.12.2023
Tilføjet 1.12.2023
This report describes the effectiveness of COVID-19 mRNA vaccines among infants and children aged 6 months-4 years.
Læs mere
83
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries
ECDC
ECDC COVID-19 updates, 30.11.2023
Tilføjet 30.11.2023
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community.
Læs mere
84
COVID Vax T-Cell Responses Help B-Cell–Deficient Patients
Medscape Infectious Diseases, 30.11.2023
Tilføjet 30.11.2023
The findings demonstrate how vaccine-induced T-cell responses could potentially reduce COVID-19 severity, the authors write. Medscape Medical News
Læs mere
85
New CDC Advisory Once Again Flags BA.2.86 COVID Variant
Medscape Infectious Diseases, 30.11.2023
Tilføjet 30.11.2023
An emerging variant of COVID-19 called BA.2.86 that caused alarm earlier this summer has landed on the CDC\'s radar again. WebMD Health News
Læs mere
86
Reporting Protocol for integrated respiratory virus surveillance, version 1.3
ECDC
ECDC COVID-19 updates, 28.11.2023
Tilføjet 28.11.2023
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
87
Pandemic Tied to a 50% Drop in Memory, Executive Function
Medscape Infectious Diseases, 27.11.2023
Tilføjet 27.11.2023
The first year of the COVID-19 pandemic is associated with a 50% decline in working memory and executive function among older adults, a new UK study suggests. Medscape Medical News
Læs mere
88
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, F Annabel Niessen, Ausenda Machado, Odile Launay, Sarah Denayer, Lucie Seyler, Joaquin Baruch, Cristina Burgui, Isabela I Loghin, Lisa Domegan, Roberta Vaikutytė, Petr Husa, George Panagiotakopoulos, Nassera Aouali, Ralf Dürrwald, Jennifer Howard, Francisco Pozo, Bartolomé Sastre-Palou, Diana Nonković, Mirjam J Knol, Irina Kislaya, Liem binh Luong Nguyen, Nathalie Bossuyt, Thomas Demuyser, Aušra Džiugytė, Iván Martínez-Baz, Corneliu Popescu, Róisín Duffy, Monika Kuliešė, Lenka Součková, Stella Michelaki, Marc Simon, Janine Reiche, María Teresa Otero-Barrós, Zvjezdana Lovrić Makarić, Patricia CJL Bruijning-Verhagen, Verónica Gomez, Zineb Lesieur, Cyril Barbezange, Els Van Nedervelde, Maria-Louise Borg, Jesús Castilla, Mihaela Lazar, Joan O’Donnell, Indrė Jonikaitė, Regina Demlová, Marina Amerali, Gil Wirtz, Kristin Tolksdorf, Marta Valenciano, Sabrina Bacci, Esther Kissling, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose
Læs mere
89
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, Joaquin Baruch, Sarah Denayer, Lucie Seyler, Lisa Domegan, Odile Launay, Ausenda Machado, Cristina Burgui, Roberta Vaikutyte, F Annabel Niessen, Isabela I Loghin, Petr Husa, Nassera Aouali, George Panagiotakopoulos, Kristin Tolksdorf, Judit Krisztina Horváth, Jennifer Howard, Francisco Pozo, Virtudes Gallardo, Diana Nonković, Aušra Džiugytė, Nathalie Bossuyt, Thomas Demuyser, Róisín Duffy, Liem binh Luong Nguyen, Irina Kislaya, Iván Martínez-Baz, Giedre Gefenaite, Mirjam J Knol, Corneliu Popescu, Lenka Součková, Marc Simon, Stella Michelaki, Janine Reiche, Annamária Ferenczi, Concepción Delgado-Sanz, Zvjezdana Lovrić Makarić, John Paul Cauchi, Cyril Barbezange, Els Van Nedervelde, Joan O’Donnell, Christine Durier, Raquel Guiomar, Jesús Castilla, Indrė Jonikaite, Patricia CJL Bruijning-Verhagen, Mihaela Lazar, Regina Demlová, Gil Wirtz, Marina Amerali, Ralf Dürrwald, Mihály Pál Kunstár, Esther Kissling, Sabrina Bacci, Marta Valenciano, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received
Læs mere
90
Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
Bette Liu, Sandrine Stepien, Ketaki Sharma and Kristine Macartney
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 given > 180 days earlier, the relative vaccine effectiveness against COVID-19 death of a bivalent (ancestral/BA.1 or ancestral/BA.4-5) booster given 8 to 90 days earlier was 66.0% (95%CI: 57.6 to 72.2%) and that of a monovalent ancestral booster given 8 to 90 days earlier was 44.7% (95%CI: 23.9 to 59.7%).
Læs mere
91
Notes from the Field: Diagnosis of Congenital Syphilis and Syphilis Among Females of Reproductive Age Before and During the COVID-19 Pandemic - Chicago, 2015-2022
Morbidity and Mortality Weekly Report (MMWR), 23.11.2023
Tilføjet 23.11.2023
This report describes increases in cases of congenital syphilis during the COVID-19 pandemic.
Læs mere
92
Early detection of the emerging SARS-CoV-2 BA.2.86 lineage through integrated genomic surveillance of wastewater and COVID-19 cases in Sweden, weeks 31 to 38 2023
Carmen Espinosa-Gongora, Carlo Berg, Moa Rehn, Javier Edo Varg, Lena Dillner, Neus Latorre-Margalef, Anna J Székely, Emmi Andersson and Elin Movert
Eurosurveillance latest updates, 17.11.2023
Tilføjet 17.11.2023
The SARS-CoV-2 BA.2.86 Omicron subvariant was first detected in wastewater in Sweden in week 31 2023, using 21 highly specific markers from the 50 investigated. We report BA.2.86’s introduction and subsequent spread to all 14 regions performing wastewater sampling, and on 70 confirmed COVID-19 cases, along with the emergence of sublineages JN.1 and JN.2. Further, we investigated two novel mutations defining the unique BA.2.86 branching in Sweden. Our integrated approach enabled variant tracking, offering evidence for well-informed public health interventions.
Læs mere
93
Rebound in community antibiotic consumption after the observed decrease during the COVID-19 pandemic, EU/EEA, 2022
Cèlia Ventura-Gabarró, Vivian H Leung, Vera Vlahović-Palčevski, Anna Machowska, Dominique L Monnet, Liselotte Diaz Högberg and ESAC-Net study group
Eurosurveillance latest updates, 17.11.2023
Tilføjet 17.11.2023
We observed a rebound in consumption of antibacterials for systemic use (ATC J01) in the community sector in the European Union/European Economic Area during 2021 and 2022, after an observed decrease between 2019 and 2020. The rates in 2022 returned to pre-COVID-19-pandemic levels and were exceeded in 13 countries. Although these patterns could partly be a result of changes in disease transmission during the study period, it could also reflect a lost opportunity to strengthen and reinforce prudent antibiotic use.
Læs mere
94
Efterårets covid-19-vacciner reducerer risikoen for indlæggelse med 75 procent
Statens Serum Institut, 16.11.2023
Tilføjet 16.11.2023
De variantopdaterede covid-19-vacciner, som er rettet mod nyere varianter af coronavirus, og som er blevet givet siden oktober i år, giver god beskyttelse mod alvorlig sygdom.
Læs mere
95
COVID-19 Antivirals Can Trigger Viral Rebound
Medscape Infectious Diseases, 14.11.2023
Tilføjet 14.11.2023
Though antivirals are critical for reducing severe COVID-19 symptoms, researchers suggested that the medication may not always be needed for milder cases. Medscape Medical News
Læs mere
96
Pandemic Tied to a 50% Drop in Memory, Executive Function
Medscape Infectious Diseases, 13.11.2023
Tilføjet 13.11.2023
A 50% decline in working memory and executive function among older adults in the United Kingdom during the first year of the COVID-19 pandemic is linked to an increase in known risk factors for dementia. Medscape Medical News
Læs mere
97
Declines in Influenza Vaccination Coverage Among Health Care Personnel in Acute Care Hospitals During the COVID-19 Pandemic - United States, 2017-2023
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes declines in influenza vaccination coverage among health care personnel working in hospitals during the COVID-19 pandemic.
Læs mere
98
Influenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care Personnel - National Healthcare Safety Network, United States, 2022-23 Influenza Season
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes the percentage of health care personnel working in hospitals and nursing homes who received a flu vaccine and the percentage who received a COVID-19 vaccine.
Læs mere
99
PCR testing of traced contacts for SARS-CoV-2 in England, January to July 2021
Toby Nonnenmacher, Niharika Dandamudi, Matthias Erwin Futschik, Sarah A Tunkel, Raghavendran Kulasegaran-Shylini, Nick Germanacos, Joanna Cole-Hamilton, Edward Blandford, Ashley Goddard, Joe Hillier, Stephen Finer, Susan Hopkins and Tom Fowler
Eurosurveillance latest updates, 3.11.2023
Tilføjet 3.11.2023
BackgroundThe NHS Test and Trace (NHSTT) programme was established in May 2020 in England to deliver SARS-CoV-2 testing and contact tracing in order to identify infected individuals and reduce COVID-19 spread. To further control transmission, people identified as contacts were asked to self-isolate for 10 days and test only if they became symptomatic. From March 2021, eligibility criteria for PCR testing expanded to include asymptomatic contacts of confirmed cases. AimTo analyse testing patterns of contacts before and after the change in testing guidance in England to assess the impact on PCR testing behaviour with respect to symptom status and contact type. MethodsTesting and contact tracing data were extracted from the national data systems and linked. Subsequently, descriptive statistical analysis was applied to identify trends in testing behaviour. ResultsBetween 1 January and 31 July 2021, over 5 million contacts were identified and reached by contact tracers; 42.3% took a PCR test around the time they were traced. Overall positivity rate was 44.3% and consistently higher in symptomatic (60–70%) than asymptomatic (around 20%, March–June) contacts. The proportion of tests taken by asymptomatic contacts increased over time, especially after the change in testing guidance. No link was observed between uptake of PCR tests and vaccination coverage. Fully vaccinated contacts showed lower positivity (23.8%) than those with one dose (37.2%) or unvaccinated (51.0%). ConclusionAlmost 1 million asymptomatic contacts were tested for SARS-CoV-2, identifying 214,056 positive cases, demonstrating the value of offering PCR testing to this group.
Læs mere
100
No Increase in MS Disease Activity Due to COVID-19
Medscape Infectious Diseases, 3.11.2023
Tilføjet 3.11.2023
COVID-19 has no impact on disease activity, progression, or cognitive performance in patients with multiple sclerosis. Medscape Medical News
Læs mere